<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156587">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02151292</url>
  </required_header>
  <id_info>
    <org_study_id>PHL-093 / NCI 9568</org_study_id>
    <nct_id>NCT02151292</nct_id>
  </id_info>
  <brief_title>A Study Comparing AZD-1775 (MK-1775) and Gemcitabine With Gemcitabine Alone in Ovarian, Peritoneal or Fallopian Tube Cancers</brief_title>
  <official_title>A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD1775 (MK1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <authority>Canada: Health Canada</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 (the second phase in testing a new drug or drug combination, to see how
      useful the drug or combination is) of chemotherapy drug, gemcitabine, when given alone or in
      combination with investigational drug, AZD 1775 (also called MK-1775), in patients with
      recurrent (the cancer has returned), platinum-resistant (the cancer does not respond to
      platinum-based therapies) ovarian, peritoneal or fallopian tube cancers.

      Gemcitabine is a chemotherapy drug commonly used to treat patients with recurrent,
      platinumresistant ovarian, peritoneal or fallopian tube cancers. Gemcitabine works by
      preventing tumor cells from multiplying by damaging their DNA, which in turn stops the tumor
      from growing. However, a protein, called Wee1, may play a role in helping to repair damaged
      tumor cells, so that the tumor continues to grow.

      AZD 1775 (MK-1775) is a new drug which may block Wee1 protein activity. When given in
      combination with gemcitabine, AZD 1775 (MK-1775) may help prevent the Wee1 protein from
      repairing damaged tumor cells without causing harm to normal cells. This is believed to
      increase the effectiveness of gemcitabine.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression free survival (in months) of gemcitabine and AZD 1775 (MK 1775) compared to gemcitabine alone</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tumor size (in millimeters) of gemcitabine and AZD 1775 (MK 1775) compared to gemcitabine alone</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in levels of CA125 of gemcitabine and AZD 1775 (MK 1775) compared to gemcitabine alone</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (in months) of gemcitabine and AZD 1775 (MK 1775) compared to gemcitabine alone</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total incidence of adverse events by event and rate</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of TP53 mutations compared to response to treatment</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of p53 protein compared to response to treatment</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Epithelial Ovarian Carcinoma</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <condition>Fallopian Tube Carcinoma</condition>
  <condition>Platinum-resistant</condition>
  <condition>Platinum-refractory</condition>
  <arm_group>
    <arm_group_label>AZD 1775 (MK 1775) and gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine: 1000 mg/m2, intravenously on Days 1, 8, and 15 of every 28 day cycle.
AZD 1775 (MK 1775): 200 mg, by mouth, once a day on Days 1, 2, 8, 9, 15, and  16 of every 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD 1775 (MK 1775) placebo and gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine: 1000 mg/m2, intravenously on Days 1, 8, and 15 of every 28 day cycle.
AZD 1775 (MK 1775) placebo: by mouth, once a day on Days 1, 2, 8, 9, 15, and  16 of every 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD 1775 (MK 1775)</intervention_name>
    <arm_group_label>AZD 1775 (MK 1775) and gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AZD 1775 (MK 1775) placebo</intervention_name>
    <arm_group_label>AZD 1775 (MK 1775) placebo and gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>AZD 1775 (MK 1775) and gemcitabine</arm_group_label>
    <arm_group_label>AZD 1775 (MK 1775) placebo and gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Measurable, platinum resistant/refractory epithelial ovarian, primary peritoneal or
             fallopian-tube carcinoma

          -  Any number of prior lines of therapy

          -  Completed any prior chemotherapy, radiotherapy or major surgery at least 4 weeks
             before receiving study treatment.

          -  Age 18 years or older on day of consent.

          -  ECOG performance status 2 or less

          -  Life expectancy greater than 3 months

          -  Normal organ and marrow function

          -  Can tolerate oral medication and no bowel obstruction

          -  Disease that is amenable to biopsy and willing to have biopsies

          -  Agree to contraception, not pregnant

          -  Understand and sign consent

        Exclusion Criteria:

          -  Previously received gemcitabine for t recurrent disease

          -  Receiving other investigational agents

          -  Unstable brain metastases

          -  History of allergic reactions to AZD 1775 (MK-1775) or gemcitabine

          -  Receiving sensitive CYP3A4 substrates, CYP3A4 substrates with a narrow therapeutic
             index, moderate to potent inhibitors / inducers of CYP3A4.

          -  Pregnant/breastfeeding

          -  HIV positive on combination antiretroviral therapy

          -  Uncontrolled intercurrent illness including, but not limited to, myocardial
             infarction within 6 months, congestive heart failure, symptomatic congestive heart
             failure, unstable angina pectoris, active cardiomyopathy, unstable ventricular
             arrhythmia, uncontrolled hypertension, uncontrolled psychotic disorders, serious
             infections, active peptic ulcer disease, active liver disease or cerebrovascular
             disease with previous stroke, or psychiatric illness/social situations that would
             limit compliance with study requirements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Oza, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amit Oza, M.D.</last_name>
    <phone>416-946-2818</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lainie Martin, M.D.</last_name>
      <phone>215-728-3889</phone>
    </contact>
    <investigator>
      <last_name>Lainie Martin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prafull Ghatage, M.D.</last_name>
      <phone>(403) 521-3721</phone>
    </contact>
    <investigator>
      <last_name>Prafull Ghatage, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Hoskins, M.D.</last_name>
      <phone>(604) 877-6000</phone>
    </contact>
    <investigator>
      <last_name>Paul Hoskins, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Holger (Hal) Hirte, M.D.</last_name>
      <phone>(905) 387-9495</phone>
    </contact>
    <investigator>
      <last_name>Holger (Hal) Hirte, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Welch, M.D.</last_name>
      <phone>(519) 685-8640</phone>
    </contact>
    <investigator>
      <last_name>Stephen Welch, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johanne Weberpals, M.D.</last_name>
      <phone>(613) 737-8899</phone>
      <phone_ext>76462</phone_ext>
    </contact>
    <investigator>
      <last_name>Johanne Weberpals, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amit Oza, M.D.</last_name>
      <phone>416-946-2818</phone>
    </contact>
    <investigator>
      <last_name>Amit Oza, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD 1775</keyword>
  <keyword>MK-1775</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>capsules</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
